Tacrolimus and nonsteroidal anti-inflammatory drugs: An association to be avoided

American Journal of Nephrology

Volumn 25, Issue 4, 2005, Pages 327-334

  Soubhia, Rosa Maria C ^a   Mendes, Glória Elisa F ^a   Mendonça, Francine Zocoler ^a   Baptista, Maria Alice S ^a   Cipullo, José Paulo ^a   Burdmann, Emmanuel A ^a,b  

^a Santa Casa de Misericórdia de São José Do Rio Preto Hospital   (Brazil)

^b NONE   (Brazil)

Author keywords

Acute nephrotoxicity; Acute renal failure; COX 1; COX 2; Diclofenac; Nonsteroidal anti inflammatory drugs; Rofecoxib; Selective cyclooxygenase inhibitors; Tacrolimus

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; SODIUM CHLORIDE; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CELL VACUOLE; CONTROLLED STUDY; DEGENERATION; DRUG BLOOD LEVEL; GLOMERULUS FILTRATION RATE; KIDNEY BLOOD FLOW; KIDNEY TUBULE; KIDNEY TUBULE CELL; KIDNEY VASCULAR RESISTANCE; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SODIUM RESTRICTION; WEIGHT REDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; DRUG SYNERGISM; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY DISEASES; LACTONES; MALE; MODELS, ANIMAL; RATS; SULFONES; TACROLIMUS;

EID: 23844528106     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086569     Document Type: Article

References (38)

1. Olyaei AJ, de Mattos AM, Bennett WM: Nephrotoxicity of immunosuppressive drugs: New insight and preventive strategies. Curr Opin Crit Care 2001;7:384-389.
2. Whelton A: Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundations and clinical implications. Am J Med 1999;106:13S-24S.
3. Kondo H, Abe T, Hashimoto H, Uchida S, Irimajiri S, Hara M, Sugawara S: Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo controlled dose-finding study. J Rheumatol 2004;31:243-251.
4. Sheiner PA, Mor E, Chodoff L, Glabman S, Emre S, Schwartz ME, Miller CM: Acute renal failure associated with the use of ibuprofen in two liver transplant recipients on FK506. Transplantation 1994;57:1132-1133.
5. Vane JR, Bakhle YS, Botting RM: Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97-120.
6. Kaplan-Machlis B, Klostermeyer BS: The cyclooxygenase-2 inhibitors: safety and effectiveness. Ann Pharmacother 1999;33:979-988.
7. Brater DC: Anti-inflammatory agents and renal function. Semin Arthritis Rheum 2002;32:33-42.
8. Black SC, Brideau C, Cirino M, Belley M, Bosquet J, Chan CC, Rodger IW: Differential effect of a selective cyclooxygenase-2 inhibitor versus indomethacin on renal blood flow in conscious volume-depleted dogs. J Cardiovasc Pharmacol 1998;32:686-694.
9. Perazella MA, Eras J: Are selective COX-2 inhibitors nephrotoxic? Am J Kidney Dis 2000;35:937-940.
10. Morales E, Mucksavage JJ: Cyclooxygenase-2 inhibitor-associated acute renal failure: case report with rofecoxib and review of the literature. Pharmacotherapy 2002;22:1317-1321.
11. Papaioannides D, Bouropoulos C, Sinapides D, Korantzopoulos P, Akritidis N: Acute renal dysfunction associated with selective COX-2 inhibitor therapy. Int Urol Nephrol 2001;33:609-611.
12. Reinhold SW, Fischereder M, Riegger GA, Kramer BK: Acute renal failure after administration of a single dose of a highly selective COX-2 inhibitor. Clin Nephrol 2003;60:295-296.
13. Woywodt A, Schwarz A, Mengel M, Haller H, Zeidler H, Kohler L: Nephrotoxicity of selective COX-2 inhibitors. J Rheumatol 2001;28:2133-2135.
14. Ahmad SR, Kortepeter C, Brinker A, Chen M, Beitz J: Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf 2002;25:537-544.
15. Braden GL, O'Shea MH, Mulhern JG, Germain MJ: Acute renal failure and hyperkalaemia associated with cyclooxygenase-2 inhibitors. Nephrol Dial Transplant 2004;19:1149-1153.
16. Torres-Lopez JE, Lopez-Munoz FJ, Castaneda-Hernandez G, Flores-Murrieta FJ, Granados-Soto V: Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of diclofenac in the rat. J Pharmacol Exp Ther 1997;282:685-690.
17. Chan CC, Boyce S, Brideau C, et al: Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 1999;290:551-560.
18. Hadad SJ, Souza ER, Ferreira AT, Oshiro ME, Boim MA, Razvickas CV, Moura LA, Schor N: FK 506: effects on glomerular hemodynamics and on mesangial cells in culture. Kidney Int 1995;48:56-64.
19. Textor SC, Wiesner R, Wilson DJ, Porayko M, Romero JC, Burnett JC Jr, Gores G, Hay E, Dickson ER, Krom RA: Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation 1993;55:1332-1339.
20. Mitamura T, Yamada A, Ishida H, Fujihira S, Ohara K, Noguchi H, Mine Y: Tacrolimus (FK506)-induced nephrotoxicity in spontaneous hypertensive rats. J Toxicol Sci 1994;19:219-226.
21. Butani L, Afshinnik A, Johnson J, Javaheri D, Peck S, German JB, Perez RV: Amelioration of tacrolimus-induced nephrotoxicity in rats using juniper oil. Transplantation 2003;76:306-311.
22. Altman RD, Perez GO, Sfakianakis GN: Interaction of cyclosporine A and nonsteroidal antiinflammatory drugs on renal function in patients with rheumatoid arthritis. Am J Med 1992;93:396-402.
23. Deray G, Le Hoang P, Aupetit B, Achour A, Rottembourg J, Baumelou A: Enhancement of cyclosporine A nephrotoxicity by diclofenac. Clin Nephrol 1987;27:213-214.
24. Schiff MH, Whelton A: Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis. Semin Arthritis Rheum 2000;30:196-208.
25. Sturrock ND, Lang CC, Struthers AD: Indomethacin and cyclosporin together produce marked renal vasoconstriction in humans. J Hypertens 1994;12:919-924.
26. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR: TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991;266:12866-12872.
27. Gambaro G, Perazella MA: Adverse renal effects of anti-inflammatory agents: Evaluation of selective and nonselective cyclooxygenase inhibitors. J Intern Med 2003;253:643-652.
28. Harris RC Jr: Cyclooxygenase-2 inhibition and renal physiology. Am J Cardiol 2002;89:10D-17D.
29. Kramer BK, Kammerl MC, Komhoff M: Renal cyclooxygenase-2 (COX-2). Physiological, pathophysiological, and clinical implications. Kidney Blood Press Res 2004;27:43-62.
30. Harris RC: Cyclooxygenase-2 in the kidney. J Am Soc Nephrol 2000;11:2387-2394.
31. Breyer MD, Hao C, Qi Z: Cyclooxygenase-2 selective inhibitors and the kidney. Curr Opin Crit Care 2001;7:393-400.
32. Bertolini A, Ottani A, Sandrini M: Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks. Curr Med Chem 2002;9:1033-1043.
33. Khan KN, Venturini CM, Bunch RT, Brassard JA, Koki AT, Morris DL, Trump BF, Maziasz TJ, Alden CL: Interspecies differences in renal localization of cyclooxygenase isoforms: Implications in nonsteroidal antiinflammatory drug-related nephrotoxicity. Toxicol Pathol 1998;26:612-620.
34. Van Hecken A, Schwartz JI, Depre M, De Lepeleire I, Dallob A, Tanaka W, Wynants K, Buntinx A, Arnout J, Wong PH, Ebel DL, Gertz BJ, De Schepper PJ: Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000;40:1109-1120.
35. Andoh TF, Burdmann EA, Lindsley J, Houghton DC, Bennett WM: Enhancement of FK506 nephrotoxicity by sodium depletion in an experimental rat model. Transplantation 1994;57:483-489.
36. Sanders LR: Exercise-induced acute renal failure associated with ibuprofen, hydrochlorothiazide, and triamterene. J Am Soc Nephrol 1995;5:2020-2023.
37. de Mattos AM, Olyaei AJ, Bennett WM: Pharmacology of immunosuppressive medications used in renal diseases and transplantation. Am J Kidney Dis 1996;28:631-667.
38. Christians U, Schmidt G, Bader A, Lampen A, Schottmann R, Linck A, Sewing KF: Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. Br J Clin Pharmacol 1996;41:187-190.